Duncan Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 16-12-2024
- Paid Up Capital ₹ 0.30 M
as on 16-12-2024
- Company Age 19 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.22 Cr
as on 16-12-2024
- Revenue -1.12%
(FY 2020)
- Profit 13.94%
(FY 2020)
- Ebitda 13.55%
(FY 2020)
- Net Worth -41.17%
(FY 2020)
- Total Assets -52.58%
(FY 2020)
About Duncan Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 0.30 M.
The company currently has active open charges totaling ₹1.22 Cr.
Ida Ebenezar and Varadarajan Dhivyalakshmi serve as directors at the Company.
- CIN/LLPIN
U24231TN2005PTC056343
- Company No.
056343
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 May 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Duncan Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ida Ebenezar  | Director | 20-Apr-2020 | Current |
| Varadarajan Dhivyalakshmi | Director | 20-Apr-2020 | Current |
Financial Performance and Corporate Structure Insights of Duncan Pharma.
Duncan Pharma Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 1.12% decrease. The company also saw a substantial improvement in profitability, with a 13.94% increase in profit. The company's net worth observed a substantial decline by a decrease of 41.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Duncan Pharma?
In 2020, Duncan Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Kniss Laboratories Private LimitedActive 36 years 1 monthVaradarajan Dhivyalakshmi is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Through Dy. Director Of Industries Single Window Clearance Agency Creation Date: 24 Nov 2010 | ₹0.66 M | Open |
Karur Vysya Bank Limited Creation Date: 23 Jun 2006 | ₹4.00 M | Open |
Karur Vysya Bank Ltd. Creation Date: 23 Jun 2006 | ₹7.50 M | Open |
How Many Employees Work at Duncan Pharma?
Unlock and access historical data on people associated with Duncan Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Duncan Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Duncan Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
